PE20141183A1 - Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares - Google Patents
Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos ocularesInfo
- Publication number
- PE20141183A1 PE20141183A1 PE2014000246A PE2014000246A PE20141183A1 PE 20141183 A1 PE20141183 A1 PE 20141183A1 PE 2014000246 A PE2014000246 A PE 2014000246A PE 2014000246 A PE2014000246 A PE 2014000246A PE 20141183 A1 PE20141183 A1 PE 20141183A1
- Authority
- PE
- Peru
- Prior art keywords
- bacteriochlorophyl
- treatment
- sensitizers
- disorders
- compounds
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 235000019804 chlorophyll Nutrition 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002428 photodynamic therapy Methods 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002784 sclerotic effect Effects 0.000 abstract 1
- 230000003313 weakening effect Effects 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526414P | 2011-08-23 | 2011-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141183A1 true PE20141183A1 (es) | 2014-10-05 |
Family
ID=46889394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000246A PE20141183A1 (es) | 2011-08-23 | 2012-08-23 | Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9452172B2 (enExample) |
| EP (1) | EP2747763B1 (enExample) |
| JP (1) | JP6215203B2 (enExample) |
| KR (1) | KR101962991B1 (enExample) |
| CN (1) | CN103930108B (enExample) |
| AU (1) | AU2012298156B2 (enExample) |
| BR (1) | BR112014004306A2 (enExample) |
| CA (1) | CA2846011C (enExample) |
| CL (1) | CL2014000432A1 (enExample) |
| DK (1) | DK2747763T3 (enExample) |
| ES (1) | ES2856698T3 (enExample) |
| HK (1) | HK1199412A1 (enExample) |
| HU (1) | HUE053321T2 (enExample) |
| IN (1) | IN2014CN02153A (enExample) |
| MX (1) | MX360683B (enExample) |
| PE (1) | PE20141183A1 (enExample) |
| PT (1) | PT2747763T (enExample) |
| RU (1) | RU2632439C2 (enExample) |
| WO (1) | WO2013027222A1 (enExample) |
| ZA (1) | ZA201402056B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| JP6049712B2 (ja) | 2011-07-08 | 2016-12-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 |
| EP2830637B1 (en) | 2012-03-29 | 2024-08-21 | Epion Therapeutics, Inc. | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| RU2635185C2 (ru) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости |
| CN116832158A (zh) | 2015-07-21 | 2023-10-03 | 艾维德洛公司 | 用光敏剂治疗眼睛的系统和方法 |
| CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| CN105601638B (zh) * | 2016-01-28 | 2018-10-26 | 东北林业大学 | 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用 |
| EP3442481B1 (en) | 2016-04-13 | 2023-06-28 | Avedro, Inc. | Systems for delivering drugs to an eye |
| US20170319329A1 (en) * | 2016-05-05 | 2017-11-09 | David Muller | Corneal Implant Systems and Methods |
| CA3046668A1 (en) * | 2017-01-03 | 2018-07-12 | Vitrean, Inc. | Methods and devices for treating a retinal detachment |
| CN111194232B (zh) * | 2017-08-02 | 2023-01-31 | 芝加哥大学 | 纳米级金属有机层和金属有机纳米片 |
| CN109091685A (zh) * | 2018-08-10 | 2018-12-28 | 北京市眼科研究所 | 一种对角膜炎提取细菌病原体的灭活方法 |
| WO2020086697A1 (en) * | 2018-10-24 | 2020-04-30 | California Institute Of Technology | Treatment of myopia and other ocular conditions using singlet oxygen |
| US11702546B2 (en) | 2018-10-24 | 2023-07-18 | California Institute Of Technology | Near-infrared heptamethine dyes for generation of singlet oxygen |
| EP3890741A1 (en) * | 2018-12-04 | 2021-10-13 | Avedro Inc. | Compounds and compositions for eye treatments |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102645A (en) | 1992-07-26 | 1998-02-22 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| RU2201219C2 (ru) * | 2001-04-24 | 2003-03-27 | Макаров Константин Алексеевич | Фармакологическая композиция пролонгированного действия |
| WO2003028628A2 (en) | 2001-10-03 | 2003-04-10 | Miravant Pharmaceuticals, Inc. | Photosensitizing carbamate derivatives |
| IL152900A0 (en) | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| CN1980661B (zh) * | 2004-06-07 | 2011-09-28 | 耶达研究及发展有限公司 | 阳离子细菌叶绿素衍生物及其用途 |
| JP2010502574A (ja) * | 2006-08-23 | 2010-01-28 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用 |
| KR101551590B1 (ko) | 2006-10-24 | 2015-09-08 | 캘리포니아 인스티튜트 오브 테크놀로지 | 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법 |
| RU2404768C1 (ru) * | 2009-10-28 | 2010-11-27 | Федеральное агентство по науке и инновациям | Глазные капли |
| WO2011099602A1 (ja) * | 2010-02-12 | 2011-08-18 | 学校法人日本大学 | ポルフィリン誘導体および放射線力学療法におけるその使用 |
-
2012
- 2012-08-23 KR KR1020147007481A patent/KR101962991B1/ko active Active
- 2012-08-23 PT PT127624054T patent/PT2747763T/pt unknown
- 2012-08-23 EP EP12762405.4A patent/EP2747763B1/en active Active
- 2012-08-23 CN CN201280045801.9A patent/CN103930108B/zh active Active
- 2012-08-23 HU HUE12762405A patent/HUE053321T2/hu unknown
- 2012-08-23 DK DK12762405.4T patent/DK2747763T3/da active
- 2012-08-23 JP JP2014526601A patent/JP6215203B2/ja active Active
- 2012-08-23 BR BR112014004306A patent/BR112014004306A2/pt not_active IP Right Cessation
- 2012-08-23 IN IN2153CHN2014 patent/IN2014CN02153A/en unknown
- 2012-08-23 ES ES12762405T patent/ES2856698T3/es active Active
- 2012-08-23 HK HK14113090.6A patent/HK1199412A1/xx unknown
- 2012-08-23 WO PCT/IL2012/050325 patent/WO2013027222A1/en not_active Ceased
- 2012-08-23 RU RU2014110784A patent/RU2632439C2/ru active
- 2012-08-23 US US14/240,328 patent/US9452172B2/en active Active
- 2012-08-23 PE PE2014000246A patent/PE20141183A1/es not_active Application Discontinuation
- 2012-08-23 CA CA2846011A patent/CA2846011C/en active Active
- 2012-08-23 AU AU2012298156A patent/AU2012298156B2/en not_active Ceased
- 2012-08-23 MX MX2014002107A patent/MX360683B/es active IP Right Grant
-
2014
- 2014-02-21 CL CL2014000432A patent/CL2014000432A1/es unknown
- 2014-03-20 ZA ZA2014/02056A patent/ZA201402056B/en unknown
-
2016
- 2016-08-18 US US15/240,221 patent/US20160354468A1/en not_active Abandoned
-
2018
- 2018-11-20 US US16/196,537 patent/US11058772B2/en active Active
-
2021
- 2021-07-08 US US17/370,743 patent/US20210330792A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140088514A (ko) | 2014-07-10 |
| AU2012298156A1 (en) | 2014-04-10 |
| KR101962991B1 (ko) | 2019-03-27 |
| HUE053321T2 (hu) | 2021-06-28 |
| BR112014004306A2 (pt) | 2017-03-28 |
| ZA201402056B (en) | 2015-11-25 |
| US20210330792A1 (en) | 2021-10-28 |
| ES2856698T3 (es) | 2021-09-28 |
| RU2632439C2 (ru) | 2017-10-04 |
| CL2014000432A1 (es) | 2014-11-28 |
| RU2014110784A (ru) | 2015-09-27 |
| AU2012298156B2 (en) | 2017-08-17 |
| CA2846011A1 (en) | 2013-02-28 |
| EP2747763B1 (en) | 2020-12-30 |
| US20140378888A1 (en) | 2014-12-25 |
| CN103930108A (zh) | 2014-07-16 |
| US9452172B2 (en) | 2016-09-27 |
| HK1199412A1 (en) | 2015-07-03 |
| JP2014524465A (ja) | 2014-09-22 |
| CA2846011C (en) | 2019-10-15 |
| EP2747763A1 (en) | 2014-07-02 |
| IN2014CN02153A (enExample) | 2015-05-29 |
| PT2747763T (pt) | 2021-02-22 |
| US20190231874A1 (en) | 2019-08-01 |
| WO2013027222A1 (en) | 2013-02-28 |
| US20160354468A1 (en) | 2016-12-08 |
| DK2747763T3 (da) | 2021-03-29 |
| MX2014002107A (es) | 2015-04-16 |
| CN103930108B (zh) | 2017-05-24 |
| JP6215203B2 (ja) | 2017-10-18 |
| MX360683B (es) | 2018-11-13 |
| US11058772B2 (en) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141183A1 (es) | Sensibilizantes de (bacterioclorofila) para el tratamiento de enfermedades y trastornos oculares | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| PE20151559A1 (es) | Nuevos derivados de piridina | |
| EA201590092A1 (ru) | АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| AR047972A1 (es) | Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| AR059338A1 (es) | N-fenilbenzotriazolilo como inhibidores de c-kit | |
| AR101177A1 (es) | Inhibidores de la syk | |
| PE20181357A1 (es) | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| MA34604B1 (fr) | Derives de la pyrazine en tant que bloqueurs de l'enac | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| PE20161552A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| PE20142186A1 (es) | Derivados biciclicos de pirazinona | |
| PE20160173A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |